Jim Simons
VINC

Jim Simons’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Jim Simons’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,105
Closed -$5.81K – 3971
2024
Q4 		$5.81K Sell
1,105
-2,195
-67% -$14.4K ﹤0.01% 3531
2024
Q3 		$47.3K Sell
3,300
-3,206
-49% -$44K ﹤0.01% 3350
2024
Q2 		$105K Buy
6,506
+436
+7% +$10.9K ﹤0.01% 3175
2024
Q1 		$614K Sell
6,070
-2,731
-31% -$173K ﹤0.01% 2781
2023
Q4 		$208K Buy
8,801
+2,156
+32% +$36.2K ﹤0.01% 3121
2023
Q3 		$134K Sell
6,645
-1,310
-16% -$25.4K ﹤0.01% 3184
2023
Q2 		$207K Sell
7,955
-1,795
-18% -$51.4K ﹤0.01% 3293
2023
Q1 		$203K Buy
9,750
+700
+8% +$15.7K ﹤0.01% 3274
2022
Q4 		$185K Sell
9,050
-6,385
-41% -$120K ﹤0.01% 3445
2022
Q3 		$426K Sell
15,435
-191
-1% -$5.5K ﹤0.01% 3022
2022
Q2 		$413K Buy
15,626
+8,539
+120% +$380K ﹤0.01% 3268
2022
Q1 		$567K Buy
+7,087
New +$875K ﹤0.01% 3109
2021
Q4 		– Sell
-1,530
Closed -$495K – 4291
2021
Q3 		$495K Sell
1,530
-1,925
-56% -$562K ﹤0.01% 2897
2021
Q2 		$898K Buy
+3,455
New +$1.05M ﹤0.01% 2722

Other funds holding VINC

SRC
Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jim Simons's VINC Position: Q1 2025 in Review

Jim Simons sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q1 2025, closing a stake of 1,105 shares — an estimated $5.81K sold.

Jim Simons first reported a position in VINC in Q2 2021 and held it in 14 quarters. The position peaked at $898K in Q2 2021. 14 funds tracked by Wall St. Rank hold VINC as of Q1 2025.

  • Jim Simons reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Jim Simons sold 1,105 Vincerx Pharma, Inc. Common Stock shares in Q1 2025, an estimated $5.81K.
  • Jim Simons first reported a position in Vincerx Pharma, Inc. Common Stock in Q2 2021 and held it in 14 quarters.
  • Jim Simons's Vincerx Pharma, Inc. Common Stock position peaked at $898K in Q2 2021.
  • 14 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q1 2025.

Based on Renaissance Technologies's 13F filing for Q1 2025, filed 14 May 2025.